Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 5 | 2025 | 512 | 1.680 |
Why?
|
| Liver Neoplasms | 5 | 2025 | 224 | 1.150 |
Why?
|
| Pancreatic Neoplasms | 4 | 2025 | 218 | 1.070 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2025 | 163 | 1.030 |
Why?
|
| Neoplasms | 5 | 2022 | 1377 | 1.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 133 | 0.810 |
Why?
|
| Health Status Disparities | 3 | 2025 | 719 | 0.810 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 291 | 0.780 |
Why?
|
| Radiology | 1 | 2022 | 12 | 0.760 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2020 | 32 | 0.750 |
Why?
|
| Hawaii | 7 | 2025 | 2011 | 0.740 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 15 | 0.670 |
Why?
|
| Internal Medicine | 1 | 2020 | 32 | 0.660 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 20 | 0.640 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 495 | 0.630 |
Why?
|
| Internship and Residency | 1 | 2020 | 146 | 0.590 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 269 | 0.570 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 241 | 0.560 |
Why?
|
| Prognosis | 5 | 2025 | 861 | 0.560 |
Why?
|
| Telemedicine | 1 | 2021 | 234 | 0.530 |
Why?
|
| Humans | 28 | 2025 | 43102 | 0.500 |
Why?
|
| Middle Aged | 13 | 2025 | 12222 | 0.490 |
Why?
|
| Universities | 1 | 2020 | 559 | 0.490 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2544 | 0.490 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 2853 | 0.450 |
Why?
|
| Aged | 10 | 2025 | 8214 | 0.450 |
Why?
|
| Cholestasis | 2 | 2023 | 12 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 989 | 0.390 |
Why?
|
| Mediastinitis | 1 | 2012 | 3 | 0.380 |
Why?
|
| Mediastinal Neoplasms | 1 | 2012 | 6 | 0.380 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 13 | 0.380 |
Why?
|
| Survival Rate | 2 | 2025 | 355 | 0.370 |
Why?
|
| Male | 13 | 2025 | 23409 | 0.360 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1723 | 0.330 |
Why?
|
| Female | 14 | 2025 | 24698 | 0.330 |
Why?
|
| Perception | 2 | 2021 | 215 | 0.300 |
Why?
|
| Adult | 8 | 2025 | 13872 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 2 | 2023 | 5 | 0.250 |
Why?
|
| Endoscopy, Digestive System | 2 | 2023 | 7 | 0.250 |
Why?
|
| Prospective Studies | 4 | 2024 | 1600 | 0.230 |
Why?
|
| Age of Onset | 1 | 2025 | 114 | 0.230 |
Why?
|
| Incidence | 3 | 2025 | 1078 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 11 | 0.220 |
Why?
|
| United States | 5 | 2024 | 5205 | 0.210 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 20 | 0.210 |
Why?
|
| Endosonography | 1 | 2023 | 6 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2025 | 1759 | 0.200 |
Why?
|
| Thrombophilia | 1 | 2002 | 5 | 0.190 |
Why?
|
| Hypercalcemia | 1 | 2002 | 13 | 0.190 |
Why?
|
| Confidentiality | 1 | 2022 | 29 | 0.190 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3156 | 0.190 |
Why?
|
| Electronic Health Records | 1 | 2022 | 108 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 17 | 0.170 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 32 | 0.170 |
Why?
|
| Biopsy | 1 | 2020 | 177 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2021 | 161 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 518 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 220 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 375 | 0.150 |
Why?
|
| Choline | 1 | 2019 | 61 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 238 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 590 | 0.130 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2016 | 9 | 0.120 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 11 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 1019 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 374 | 0.120 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 157 | 0.110 |
Why?
|
| Hospitals, Community | 1 | 2015 | 13 | 0.110 |
Why?
|
| Organizational Culture | 1 | 2015 | 15 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 67 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2016 | 281 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2016 | 383 | 0.100 |
Why?
|
| Thromboembolism | 2 | 2024 | 20 | 0.100 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 8 | 0.100 |
Why?
|
| Mediastinum | 1 | 2012 | 6 | 0.100 |
Why?
|
| Necrosis | 1 | 2012 | 54 | 0.090 |
Why?
|
| Granulosa Cells | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cell Movement | 1 | 2016 | 655 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 245 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1063 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 502 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 12 | 0.070 |
Why?
|
| ras Proteins | 1 | 2008 | 54 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 56 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 161 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 223 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 257 | 0.060 |
Why?
|
| Risk Factors | 2 | 2025 | 3994 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 704 | 0.060 |
Why?
|
| Gene Expression | 1 | 2008 | 701 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 43 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2005 | 48 | 0.050 |
Why?
|
| Anilides | 1 | 2024 | 28 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2024 | 44 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 95 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 317 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 100 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 139 | 0.050 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 7 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2023 | 10 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 140 | 0.050 |
Why?
|
| Radiography | 1 | 2002 | 71 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 10 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 4 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 59 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 53 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 153 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 237 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 183 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2024 | 1604 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 154 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 539 | 0.040 |
Why?
|
| Quality of Life | 1 | 2024 | 616 | 0.040 |
Why?
|
| Smoking | 1 | 2025 | 1024 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 368 | 0.030 |
Why?
|
| Hypertension | 1 | 2024 | 835 | 0.030 |
Why?
|
| Obesity | 1 | 2025 | 1151 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 114 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 74 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 127 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 102 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 196 | 0.030 |
Why?
|
| Tyrosine | 1 | 2016 | 120 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 88 | 0.030 |
Why?
|
| Apoptosis | 2 | 2016 | 1568 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 290 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 51 | 0.030 |
Why?
|
| Leadership | 1 | 2015 | 86 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 99 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 883 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 986 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 1621 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 6644 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1455 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2009 | 27 | 0.020 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 29 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 83 | 0.020 |
Why?
|
| Heterozygote | 1 | 2009 | 110 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2009 | 76 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 346 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 2157 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 16992 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 734 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2005 | 63 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2005 | 63 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2005 | 92 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 1772 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 6081 | 0.010 |
Why?
|